BLCS 1 Overview Slides This is a compilation of slides that can be adapted to the needs of a particular group.

Slides:



Advertisements
Similar presentations
The Healthy Option Is that the Route to Funding? Sport and Recreation Alliance Annual Conference 4 th May 2011 Dr William Bird MBE GP Intelligent Health.
Advertisements

Disability, Frailty and Co-morbidity Gero 302 Jan 2012.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Readmission and Chronic illness that could benefit from end of life discussions.
Intervention with the Elderly Chapter 8. Background The elderly population is growing in industrialized countries. This is due to: – Improved medical.
Drug safety in the elderly EFNS Stockholm 2012 Barbro Westerholm Prof.em, Member of Swedish Parliament.
“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.
Aging and Obesity Claire Zizza Tenth Annual Diabetes and Obesity Conference April 19, 2011.
Senior Adult Oncology. Overview  Cancer is the leading cause of death for those years  60% of all cancers occur in patients who are 65 years or.
1 Prescribing Omissions according to START and related hospital admission in geriatric patients O. Dalleur 1, A. Spinewine 2, S. Henrard 3, C. Losseau.
Chapter 17: Geriatric Emergencies
Polypharmacy and preventing hospital admissions
Quality of care Patient-centred primary and specialist care Medication reviews Chronic condition management and disease prevention 1.
Polypharmacy May 2008 CRIT Heidi Auerbach, MD Copyright Boston University Medical Center.
To evaluate the availability of medication studies enrolling patients that are 80 years of age and older. Evaluation of Medication Studies Enrolling Patients.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
Polypill x Aspirin Project Groups 3 and 4
James B. Ray, PharmD, CPE The James A. Otterbeck Professor of Hospice & Palliative Care University of Iowa College of Pharmacy 11/18/2015.
Disability, Frailty and Co-Morbidity L. Fried et al. Gero 302 Jan 2012.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
Supporting people with dementia who also have complex physical health conditions Patricia Howie Educational Projects Manager.
TLCTLC TLCTLC LTCLTC LTCLTC Delaware Valley Geriatric Education Center When Wrong Things Happen with Medications: Risk and Prevention by Donna Miller,
Falls and Fall Prevention. Prevalence of Falls in Older Adults  33% of older adults fall each year  Falls are the leading cause of fatal and nonfatal.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Medication Management in the Older Patient. Older adults are more likely to have an Adverse Drug Reaction More likely to be on 5 or more medications Hazzard,
Aging, Health and Mental Health Prepared for distribution by the CSWE Gero-Ed Center.
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Using an EHR Template and the Beer’s List to Address Geriatric Polypharmacy Rose Family Medicine Residency Emily Gutgsell, MD Emma Bjore, MD Anna Plunkett,
Grant Macdonald.  Appropriate polypharmacy describes treatment where a patient has multiple morbidities, and/or a complex condition, that is being managed.
Palliative Care Education Module
Management of Hypertension according to JNC 7
A Welsh Overview of Pharmacy and Falls Prevention
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
Falls and Fracture Prevention Training
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Cover slide.
Hypertension JNC VIII Guidelines.
Opioids Aware A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.
Antibiotic Stewardship is Vitally Important
Prescribing.
HOPE: Heart Outcomes Prevention Evaluation study
Medication in the Elderly
Patient Safety in Transitions of Care
@Improve_Academy #WeStopMeds.
Polypharmacy In Adults: Small Test of Change
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
What’s New in Medication Management: Focus on Older Adults and Caregivers Tuesday, April 30, :00 Noon CDT Mike Varnell, RPh, CSA (214)
CQ2 – What are the priority issues for improving Australia’s health?
Acute Kidney Injury (AKI)
Multimorbidity: prevention and management
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Information for Network Providers
The ultimate goal of today’s presentation is to be able to understand the common factors/themes occurring in elderly medication incidents as well.
Chapter 1 Benefits and Risks Associated with Physical Activity
New Opportunities in Medicare
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Non-Pharmacological Therapies, Chronic Pain and Opioid Addictions
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
Age Friendly Places – Healthcare Sector
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
UNDERSTANDING DRUGS AND MEDICINCES
Frailty and Its Effect on the 4 M’s
Polypharmacy Risk Reduction in the Community: Building Local Capacity & Sustainability Through Meaningful Medication Reviews.
New Models of Care in Idiopathic Pulmonary Fibrosis
Let’s talk medicines safety
FALLS IN OLDER ADULTS Presented by: dr. menna shawkat
Presentation transcript:

BLCS 1 Overview Slides This is a compilation of slides that can be adapted to the needs of a particular group

What exactly is Polypharmacy? Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

Various Descriptive Definitions Around the World Multiple Medications One Inappropriate Medication More than 5 medications More than 5 inappropriate medications More than 10 appropriate medications Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

What is Polypharmacy? Our working definition When the theoretical benefits of multiple medications are outweighed by the negative effect of the sheer number of medications, regardless of class of medication or “appropriateness” thereof. Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

Polypharmacy is a stand-alone risk factor for morbidity and mortality Even when we control for other comorbidities and specific drug effects.

What are the risks of Polypharmacy?. Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

Cognitive function, ADL’s, Quality of Life Decreased: Cognitive function, ADL’s, Quality of Life Increased: ADE’s, Falls, Transfers to Acute Care Which leads to: Hospitalization Associated Disability Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

The drug cascade

Adverse Drug Reactions The most consistent risk factor for adverse drug reactions is: number of drugs being taken Risk rises exponentially as the number of drugs increases.

Atkin PA, Veitch PC, Veitch EM, Ogle SJ Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging 1999;14:141-152

Accumulation of minor side effects = people could feel and function better! Change in metabolism with aging Drug-drug, drug disease, drug-nutrition interactions Cycle of side effects, more tests, drug cascade-Let’s interrupt this negative cycle

So, if common side effects of most medications include…. Fatigue, weakness, muscle aches Anorexia, nausea, bloating, cramps, constipation, diarrhea Dizziness, postural instability Headaches

Accumulation of minor side effects leads to feeling… crappy CRAPPY

Hospitalization-Associated Disability Hospitalization is a sentinel event that often precipitates disability. This results in the subsequent inability to live independently and complete basic activities of daily living (ADLs). This hospitalization-associated disability occurs in approximately one-third of patients older than 70 years of age and may be triggered even when the illness that necessitated the hospitalization is successfully treated.

What Is The Scope of the Problem? Involve all members of the “Circle of Care” from the get-go Raises awareness, facilitates buy-in, prevents moral distress Respect people’s time and contributions Create review schedule in advance so team can be prepared with the correct information

Seniors In Canada (in 2012): 65.9% of all seniors (>65) on 5 or more prescription drugs 27.2% are on 10+ prescription drugs “Residential” LTC care seniors in BC: Average number of medications per patient: 9 (0-55!) About 35% of LTC patients are on 10+ medications So, how bad is this problem? All seniors (65+) in Canada, whether healthy and independent or not, are getting more than their share of prescription medications: 2/3 (65.9%) are on 5 or more, and more than ¼ are on 10 or more meds! In nursing homes, what we call residential care in BC, the numbers are even higher: about 35% are on 10 or more medications. CIHI Report: Drug Use Among Seniors on Public Drug Programs in Canada, 2012, published May 2014: https://secure.cihi.ca/free_products/Drug_Use_in_Seniors_on_Public_Drug_Programs_2012_EN_web.pdf

“Every year, one in three adults 65 or older has one or more adverse (harmful) reactions to a medication or medications.” American Geriatric Society, Beers Criteria 2012 www.americangeriatrics.org.

Polypharmacy: Medications may be inappropriate if: Goes against patient’s goals of care Lack of clear indication Adverse effects, drug interaction, allergy Incorrect duration Incorrect dose This is a broader view that incorporates the patient’s/resident’s goals of care in relation to their health status and frailty…

What Causes Polypharmacy? Patient-Centered: Change in how the elderly metabolize/tolerate medications Multiple comorbidities/symptoms Clinical Practice Guidelines Clinical uncertainty Uncertain treatment goals The pressure to “Do something” Drug companies emphasize benefits & downplay the risks System-Related: Lack of history Lack of communication Multiple prescribers-SPECIALIST consultation (10 years ago?) Acute Care admission Physician/patient/family reluctance: “Don’t change anything!” Treating side effects of another pill Free medications

Common Chronic Conditions and Polypharmacy Prevention and/or Symptom Management Cardiovascular risk: Hypertension: 2 meds (of Calcium channel blocker, ACE inhibitor, diuretic) Hypercholesterolemia: 1 med (Statin) Diabetes: 2 meds as disease progresses (Metformin + Sulfonylurea-Glicazide Atrial fibrillation: 1 med (Warfarin, NOACS) Coronary artery disease: 2 meds (Aspirin, Beta-blocker- if angina) Heart failure: 3 meds (Diuretic, ACE-I, Beta-blocker) Chronic obstructive pulmonary disease: 2 drugs (Inhalers- Sympathetic/cholinergic systems) Bone metabolism (mostly women): 2 meds (Ca, Vit D), Bisphosphonate if osteoporosis and high risk of fracture Osteoarthritis: If pain (analgesic- Acetaminophen, NSAID, opioid) Cancer: Depends on type re: long term Tx GI: Dyspepsia (Antacid), Gastroesophageal reflux disease (GERD)- H2B, PPI This slides show how medications, prescribed according to clinical practice guidelines which are developed based upon evidence for younger populations, can accumulate.

Frail Elderly Related Conditions and Polypharmacy Urinary outflow issues: 1 med (anticholinergic) Constipation: 1-2 meds Dementia: 1 drug (Donepezil covered in BC) Multi-morbidity: Meds as per previous slide Frailty: Vitamins and minerals Non-specific symptoms** End of life/palliative care: Add meds for Dyspnea, GI, Pain This slide shows how elderly, particular frail elderly, related conditions can generate additional medications over and above the usual chronic conditions.

So What Can We Do?- Evidence of Benefit For Medication Reviews In Residential care Case-control study over 1 year, mod-severe demented Israeli facility residents on ~ 7 drugs* (Garfinkel) 2.8 drugs/patient stopped (all types of medications) Only 18% drugs / 10% patients had the stopped meds restarted over a year Decr mortality (21 vs 45%)NNT 4.1 Decr acute care transf (12 vs 30%)NNT 5.5 This is when average stay is ~ 1 yr! * IMAJ 2009;9:430-434 There are 2 Garfinkel studies- this is on the more complex patients that were in a kind of TCU in acute; the other study is on community elderly so less applicable CR

Evidence- Community Elderly (Garfinkel) Algorithmic approach-we adapted 70 patients, mean age 83, 3+ co-morbidities, over 19 months, mean 8 drugs In 64 patients, recommended D/C 311 drugs (4.4 per patient overall), wide range of drugs 2% re-start for original indication (furosemide, SSRI…) No significant adverse events or deaths were attributable to discontinuation, including hospitalization 88% of patients re- ported global improvement in health Arch Intern Med. 2010;170(18):1648-1654 This is an extra slide as it was the study done in community elderly but shows great results from the same med review approach…

So What Strategies Could Make The Path To Deprescribing More Acceptable? Understand the individual health status, including chronic diseases and frailty, and the related Goals of Care… this sets the context for addressing medications Explaining as: Dosage reduction, tapering with monitoring and review- this is a valid clinical strategy as well Stating the objective as ‘Pause and Monitor’ rather than ‘deprescribing’ or ‘stopping medications’- this is a valid clinical strategy as well